EP1667729A4 - Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors - Google Patents
Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factorsInfo
- Publication number
- EP1667729A4 EP1667729A4 EP04776088A EP04776088A EP1667729A4 EP 1667729 A4 EP1667729 A4 EP 1667729A4 EP 04776088 A EP04776088 A EP 04776088A EP 04776088 A EP04776088 A EP 04776088A EP 1667729 A4 EP1667729 A4 EP 1667729A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- transcription factors
- structure based
- aptamer targeting
- phosphorodithioate
- oligonucleoside phosphorothioate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000040945 Transcription factor Human genes 0.000 title abstract 2
- 108091023040 Transcription factor Proteins 0.000 title abstract 2
- 108091023037 Aptamer Proteins 0.000 title 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000005745 host immune response Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47288803P | 2003-05-23 | 2003-05-23 | |
PCT/US2004/016246 WO2005018537A2 (en) | 2003-05-23 | 2004-05-20 | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1667729A2 EP1667729A2 (en) | 2006-06-14 |
EP1667729A4 true EP1667729A4 (en) | 2007-10-17 |
Family
ID=34215796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04776088A Withdrawn EP1667729A4 (en) | 2003-05-23 | 2004-05-20 | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1667729A4 (en) |
CA (1) | CA2526853A1 (en) |
WO (1) | WO2005018537A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910523B2 (en) * | 2003-05-23 | 2011-03-22 | Board Of Regents, The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors |
CN101217967B (en) | 2005-05-04 | 2014-09-10 | 诺松制药股份公司 | Novel use of enantiomer |
JP2012526130A (en) * | 2009-05-05 | 2012-10-25 | アルテルムネ テクフノロジエス,エルエルシー | Chemically programmable immunity |
AU2014244534B2 (en) * | 2013-03-14 | 2020-04-30 | Otsuka Pharmaceutical Co., Ltd. | Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated conditions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026260A2 (en) * | 2002-09-17 | 2004-04-01 | Archemix Corp. | Prophylactic and therapeutic hiv aptamers |
WO2005003291A2 (en) * | 2002-10-16 | 2005-01-13 | Board Of Regents Of The University Of Texas System | Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries |
WO2005032455A2 (en) * | 2003-05-23 | 2005-04-14 | Board Of Regents | Combinatorially selected phosphorodithioate aptamer targeting ap-1 |
WO2005037053A2 (en) * | 2003-05-23 | 2005-04-28 | Board Of Regents - The University Of Texas System | High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US20010034330A1 (en) * | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US6725526B2 (en) * | 2002-01-14 | 2004-04-27 | Hitachi Global Storage Technologies Netherlands B.V. | Method of forming microsuspension assemblies for direct access storage devices |
-
2004
- 2004-05-20 WO PCT/US2004/016246 patent/WO2005018537A2/en active Application Filing
- 2004-05-20 CA CA002526853A patent/CA2526853A1/en not_active Abandoned
- 2004-05-20 EP EP04776088A patent/EP1667729A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026260A2 (en) * | 2002-09-17 | 2004-04-01 | Archemix Corp. | Prophylactic and therapeutic hiv aptamers |
WO2005003291A2 (en) * | 2002-10-16 | 2005-01-13 | Board Of Regents Of The University Of Texas System | Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries |
WO2005032455A2 (en) * | 2003-05-23 | 2005-04-14 | Board Of Regents | Combinatorially selected phosphorodithioate aptamer targeting ap-1 |
WO2005037053A2 (en) * | 2003-05-23 | 2005-04-28 | Board Of Regents - The University Of Texas System | High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens |
Non-Patent Citations (1)
Title |
---|
KING DAVID J ET AL: "COMBINATORIAL SELECTION AND BINDING OF PHOSPHOROTHIOATE APTAMERS TARGETING HUMAN NF-KAPPA B RELA(P65) AND P50", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 41, no. 30, 30 July 2002 (2002-07-30), pages 9696 - 9706, XP009084286, ISSN: 0006-2960 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005018537A3 (en) | 2005-05-26 |
EP1667729A2 (en) | 2006-06-14 |
WO2005018537A2 (en) | 2005-03-03 |
CA2526853A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004016805A3 (en) | Immunostimulatory nucleic acids | |
WO2005032455A3 (en) | Combinatorially selected phosphorodithioate aptamer targeting ap-1 | |
ES2206424T3 (en) | IMMUNO STIMULANT OLIGODESOXINUCLEOTIDOS. | |
MY137619A (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | |
EP3424524A3 (en) | Cancer rna-vaccine | |
ATE426412T1 (en) | ADJUVANT INFLUENZA VACCINE | |
WO2006135434A3 (en) | Semi-soft c-class immunostimulatory oligonucleotides | |
DK1355930T3 (en) | Method for identifying, isolating and producing antigens against a specific pathogen | |
HN2006016512A (en) | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
WO2004053104A3 (en) | 5’ cpg nucleic acids and methods of use | |
NO20015073L (en) | vaccinations | |
PT1487485E (en) | Imidazoquinoline adjuvants for dna vaccines | |
DK1104306T3 (en) | Preparations of CpG and Saponin Adjuvants and Methods for Using Them | |
DE60036698D1 (en) | CHLAMYDIA ANTIGENES AND CORRESPONDING DNA FRAGMENTS AND ITS USES | |
WO2001092470A3 (en) | Dna expression vectors and methods of use | |
EP1220925B8 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
WO2011007359A3 (en) | Antigen specific multi epitope -based anti-infective vaccines | |
ZA202207790B (en) | Pharmaceutical composition and use thereof | |
WO2005049832A3 (en) | FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE | |
WO2005018537A3 (en) | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors | |
WO2005049647A3 (en) | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens | |
TNSN05052A1 (en) | Immunostimulatory nucleic acids | |
WO2005021033A3 (en) | Vaccine | |
BRPI0604365A (en) | isolated polypeptide, multi-tick vaccine composition, and use thereof | |
ATE353226T1 (en) | ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051220 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101AFI20070626BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070917 |
|
17Q | First examination report despatched |
Effective date: 20090130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090610 |